BTAIQ
Bioxcel Therapeutics Inc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsBioxcel Therapeutics Inc
Expected move
Inputs0.00%
BTAIQ weight · VTI
No changes.
No changes.
No trades yet today.
No trades yet today.
No peers for Bioxcel Therapeutics Inc yet.
No peers for Bioxcel Therapeutics Inc yet.
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
13F holdings, not covered
Not loaded
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Supply-chain ties, covered
None disclosed
Fund holders, covered
N-PORT holdings
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Annual filing, not covered
Not parsed · ties from counterparty filings
13F holdings, not covered
Not loaded
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
BioXcel Therapeutics, Inc.
Price unavailable.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of adrenergic receptor agonist dexmedetomidine for the treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immune activator for the treatment of prostate and pancreatic cancers, and solid tumors. BioXcel Therapeutics, Inc. has a collaboration with collaboration with the VA Connecticut Healthcare System and the Yale University Medical School for patients suffering from post-traumatic stress disorder related to alcohol and substance abuse disorder. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Expected move
No implied move.
+81.51%
shares held · 10 largest managers
| Manager | Value | % base | |
|---|---|---|---|
| Millennium | $2.5M | 34.22% | +9.19% |
| Oaktree | $1.6M | 22.32% | +472.27% |
| Vanguard | $1.1M | 14.87% | +343.50% |
| Oaktree | $292,000 | 3.97% | +472.29% |
| Geode | $288,000 | 3.92% | +5.25% |
| Manager | Value | % base | |
|---|---|---|---|
| Millennium | $2.5M | 34.22% | +9.19% |
| Oaktree | $1.6M | 22.32% | +472.27% |
| Vanguard | $1.1M | 14.87% | +343.50% |
| Oaktree | $292,000 | 3.97% | +472.29% |
| Geode | $288,000 | 3.92% | +5.25% |